Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS

Why It Matters

The CHMP opinion positions Cenrifki as the first BTK inhibitor targeting non‑relapsing SPMS, addressing a major unmet need and strengthening Sanofi’s neurology portfolio.

Key Takeaways

• CHMP issued positive opinion for Cenrifki in non‑relapsing SPMS
• Phase III HERCULES trial showed delayed disability progression
• Oral, brain‑penetrant BTK inhibitor targets smoldering neuroinflammation
• Regulatory filings now underway in the United States and Japan
• Potential to fill therapeutic gap for progressive MS patients

Pulse Analysis

Multiple sclerosis remains a leading cause of disability, with secondary progressive MS (SPMS) representing a therapeutic blind spot. While disease‑modifying therapies have transformed outcomes for relapsing‑remitting patients, those with non‑relapsing SPMS lack effective options to halt neurodegeneration. Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising class because they can modulate both peripheral immune cells and resident microglia, addressing the smoldering inflammation that drives disability progression. Cenrifki, Sanofi’s oral, brain‑penetrant BTK inhibitor, is engineered to achieve sustained central nervous system exposure, a critical differentiator from earlier BTK candidates that struggled with adequate brain uptake.

The CHMP’s positive opinion follows robust Phase III evidence. In the HERCULES trial, Cenrifki delayed the onset of confirmed disability progression by several months compared with placebo, a clinically meaningful benefit for patients whose disease course is defined by gradual decline rather than acute relapses. Supporting data from the GEMINI 1 and 2 studies in relapsing MS further underscore the drug’s efficacy across the disease spectrum, reinforcing its mechanism of action against neuroinflammation. The European endorsement accelerates the timeline for market entry, while Sanofi has already initiated parallel submissions in the U.S. and Japan, signaling confidence in the global applicability of the data.

If approved, Cenrifki could reshape the competitive landscape for progressive MS therapies. Existing options, such as siponimod and ocrelizumab, offer modest benefits and are administered via injection or infusion, limiting patient convenience. An oral, once‑daily BTK inhibitor would provide a differentiated, patient‑friendly alternative, potentially expanding treatment adoption. Moreover, Sanofi’s entry into the BTK space may spur further innovation, prompting rivals to accelerate their own pipelines. Investors and clinicians alike will watch the upcoming regulatory milestones closely, as Cenrifki’s success could herald a new era of disease‑modifying treatments for a patient population that has long been underserved.